"我们期待借活动促成更多'资本+技术+产业'的深度合作。"重庆市经信委医药处副处长孙清华表示，智 慧医疗作为新一代信息技术与医疗健康深度融合的产物，重庆高度重视并组建了市级智慧医疗装备产业 创新发展工作专班，出台了《重庆市智慧医疗装备产业创新发展行动计划（2025-2027年）》，旨在通 过"超常规、突破性"政策引导，推动智慧医疗装备产业突破性发展。今年1—5月，全市智慧医疗装备产 业发展取得重大进展，新增医疗器械生产企业13家，获批注册三类产品19个，同比增长111.1%，各区 县1—5月共计签约智慧医疗装备制造业项目40个，合同投资额174.6亿元；全市在建和新开工项目25 个，项目投资总额53.39亿元。重庆大学、重庆医科大学累计获得发明专利授权70项、新增科技成果98 项、实现成果落地16项。 让"技术"遇见"资本"，让"创意"找到"舞台"。7月10日，重庆市科技局、市经信委举行智慧医疗装备产 业专场投融资对接活动，共计16个项目举行了现场路演，涉及智慧检测、脑健康、活性人工骨等多个前 沿医疗健康领域。截至本月，重庆市种子投资基金已累计投资项目46个，投资金额4785万元。 参与此次路演的项目，既有高 ...

在粤港澳大湾区"一小时生活圈"加速融合的背景下，"跨境养老"正成为破解老龄化困局的新引擎。日 前，安永于广州分享《大湾区跨境养老的探索——融通、创新、未来》报告并举办专题研讨会。 报告揭示：香港65岁及以上人口占比十年间从13%飙升至19%，2050年或成全球老龄化最严重地区；澳 门老年人口抚养比同期由9%跃至16%。与此同时，"港澳药械通"政策已惠及过万人次，跨境养老社区 扩容至11家。面对资源错配与制度壁垒，与会专家呼吁以智慧医疗、金融创新与政策协同破局，构 建"医养结合+跨境互联"的湾区养老新生态。 老龄化浪潮倒逼跨境协作，港澳需求迫在眉睫 "香港可能成为全世界最老龄化地区，但跨境养老提供了成本与资源的平衡点。" 安永香港审计服务合 伙人胡嘉丽在研讨会现场指出。报告数据显示，2020年粤港澳大湾区老年人口抚养比显著攀升，香港达 27%，澳门为16%，而江门、肇庆等内地城市亦超18%。香港特区政府数据显示，本地养老院平均轮候 时间长达24个月，一张床位月均补贴高达2.5万港元，人力成本占运营费用的六成以上。 这一困境催生了北上养老的刚需。截至2024年底，"广东院舍照顾服务计划"将跨境养老机构从4家扩至 ...

以"智慧互联、精准高效"为核心定位，该智慧实验室实现了检验全流程的系统性革新。在样本传输环节，实验室采用先进的气动传输技 术，打造随采随传的物流网络，传输速度达600份/小时，仅需5秒即可将样本从门诊采血区直达检测仪器区，显著降低了人工操作强度与 差错风险。 在样本处理环节，自动化流水线借助智能识别样本唯一标识，实现了住院标本和体检标本的"一次性倾倒"。检验人员无需逐份整理，只 需将批量样本放置于进样区，系统便会自动完成分类分流，做到"同类样本集中处理"；配合智能轨道系统，样本能够被精准输送至对应 检测设备，真正实现"一管样本、多项目联动检测"。检测完成后，样本自动转入后处理冰箱，按预设规则智能分类归档，到期后自动清 理，全程可追溯。 齐鲁晚报.齐鲁壹点褚思雨通讯员许丹丹邹亦轩 6月30日，邹城市人民医院医学检验科"智慧实验室"顺利完成交付验收。作为山东省县市级医疗机构中首家智慧实验室，该项目的落地不 仅标志着邹城市医学检验服务正式迈入智能化、高效化新阶段，更成为医院智慧化建设进程中的关键里程碑。 全流程自动化 构建"无人化"检验闭环 依托"自动化系统+信息化技术"双轮驱动，实验室通过先进的MALAB中间体软 ...

智慧医疗已经成为全球医疗行业发展的新趋势，而智慧医院则是智慧医疗的重要载体。借助人工智能、云计算、大数据和物联网等新一代数字 技术，智慧医院深度整合医疗资源，优化医疗流程，提高医疗服务质量，让患者在就医过程中感受到更为便捷、舒适和安全的医疗服务。 嘉讯科技HIS系统-嘉讯医院信息管理系统 一、什么是智慧医疗？ 其实，智慧医疗是一个很"虚"的概念。不同的人，对智慧医疗有不同的理解。有人觉得它是一门学科、一种技术，也有人觉得它是一个平台、 一套体系，甚至一种商业模式。智慧医疗更像是一种理念。它是医疗信息化发展阶段的产物，是5G、云计算、大数据、AR/VR、人工智能等 技术与医疗行业进行深度融合的结果，是互联网医疗的演进。 说到医疗信息化，大家应该不会觉得陌生。早在上世纪八九十年代，我们国内就效仿国外，引进了医疗信息化技术。当时，少数有条件的大型 医院，购置了计算机软硬件，建立IT系统和数据库，用于改进医院管理工作流程，推动效率提升。 医疗信息化的落地成果，主要集中于医院的财务结算系统，以及药品等医疗物资的管理系统。进入21世纪后，随着IT技术的进一步成熟，以及 互联网的爆发，医疗信息化进入2.0阶段。越来越多的医 ...

一、中汇集团的"社会赋能方程式" 作为粤港澳大湾区规模最大的民办高等及职业教育集团，中汇集团始终将坚守"创百年名校，育华夏英才"的办学初心，通过提供高质量的教育 服务履行社会责任。民办高等教育集团的社会价值不仅体现在传授知识方面，更在于通过资源整合解决社会痛点。中汇集团围绕主业，通过"教 育公平化""产教融合""社区反哺"三维实践，重新定义行业责任边界。 中汇集团持续深化产教融合，将企业资源引入教学全链条，确保人才培养与市场需求无缝对接。 2025年7月4日，在备受瞩目的格隆汇"金格奖"年度卓越公司颁奖典礼上，中汇集团凭借其在ESG（环境、社会和公司治理）领域的卓越实践与 突出贡献，荣获"ESG社会责任卓越企业奖"。 这一殊荣是对中汇集团在ESG领域长期努力的高度认可。自2019年上市以来，中汇集团始终践行"教育即责任"的可持续发展理念，为民办高等 教育行业树立了ESG价值标杆。 二、ESG价值与商业价值共振 当前，随着ESG投资理念的日益普及，越来越多的投资者将ESG因素纳入投资决策的重要考量，认为良好的ESG表现有助于降低公司的运营风 险、提升公司的长期竞争力和投资价值。中汇集团凭借其在ESG领域的突出表 ...

Core Viewpoint - The company has signed a strategic cooperation agreement with China Pacific Life Insurance Co., Ltd. Hebei Branch to develop smart elderly care, smart healthcare, and smart medical insurance in Langfang City [1] Group 1: Strategic Cooperation - The partnership aims to create pilot projects in smart elderly care, smart healthcare, and smart medical insurance [1] - The collaboration will provide experience and references for the entire province [1] Group 2: Goals and Objectives - The cooperation focuses on optimizing the insurance system platform, expanding its functions, and enhancing data empowerment [1] - Both parties will explore collaboration in home care and nursing, community institutional care and nursing, integrated medical and elderly care, chronic disease management, and training services for caregivers [1]

Core Viewpoint - Mindray Medical aims to become one of the top ten or even top five medical device companies globally, leveraging its strong competitive position in the Chinese market, particularly in the monitoring equipment sector [4]. Group 1: Investor Relations Activities - Mindray Medical conducted a series of investor relations activities from May 19 to June 27, 2025, attracting 382 institutions and 713 investors [3]. Group 2: Competitive Advantages - The company's success is attributed to its meticulous attention to detail and solid execution across R&D, management, and sales, alongside a strong focus on employee training and welfare [5]. Group 3: Addressing Performance Challenges - Mindray identified reasons for slowing growth, including post-pandemic demand decline and trade friction, and is focusing on high-end market needs and overseas expansion to regain rapid growth [6]. Group 4: Domestic Policy Adaptation - The company views centralized procurement policies as a necessary step towards market maturity in China, which ultimately presents opportunities for leading domestic firms [7]. Group 5: International Strategy - Mindray aims for international revenue to account for 70% of its total, with over 60 overseas subsidiaries and a focus on local production and compliance with international regulations [8]. Group 6: Business Transformation - The company is preparing for a transformation in its business model by acquiring Huatai to enhance its core technology and expand into high-value consumables [9]. Group 7: Product Development and Market Position - Mindray is narrowing the gap with Roche in the chemiluminescence sector through strategic acquisitions and local production, with confidence in competing with imported brands [10]. Group 8: Data Integration and Device Advantage - The "Ruizhi Lian" data platform integrates with most mainstream devices, providing comprehensive and accurate patient data, which is a significant competitive edge [12]. Group 9: R&D Resource Allocation - The company balances R&D resources to support both core and emerging businesses, ensuring stability in main operations while fostering new growth areas [13]. Group 10: Personalized Product Development - Mindray conducts market research in target countries during product development, ensuring that products meet local clinical needs before full market launch [14]. Group 11: IVD Product Line Improvements - Mindray's MT8000 product line addresses inefficiencies found in imported brands, with ongoing efforts to enhance functionality and adapt to European market needs [15]. Group 12: MPI System Adaptation - The company is refining its MPI system to better suit the needs of its IT and consumable businesses, ensuring rapid iteration and effective project execution [16]. Group 13: Growth Challenges and Strategies - Mindray recognizes its limitations in marketing and local delivery for high-value consumables and is considering both internal development and acquisitions to address these gaps [18]. Group 14: "Sanrui" Ecosystem Strategy - The "Sanrui" ecosystem model is designed to integrate clinical data and enhance automation and intelligence in medical devices, with plans for local deployment and information security [19]. Group 15: Innovation in Product Development - Mindray emphasizes technical innovation, focusing on user needs and product performance, as demonstrated by the successful launch of its ultrasound knife [20]. Group 16: Company Overview - Founded in 1991, Mindray Medical is China's largest medical device manufacturer, with a global presence and a strong R&D team [21]. Group 17: Financial Performance - In 2024, Mindray reported a revenue of 36.73 billion, a 5.1% increase year-on-year, with a net profit of 11.67 billion, reflecting a 0.7% growth [22].

据了解，重庆市科技局围绕重大医疗装备实现国产化的目标，紧扣智慧医疗装备"高端化、智能 化、精准化"发展趋势，聚焦重大产品开发和前沿关键技术突破，编制形成了《重庆市2025年智慧医疗 装备技术创新实施方案》。该方案围绕重点领域，以快速响应机制启动实施智慧医疗装备与前沿技术专 项，每年分别组织十大重大装备研制和十大前沿技术研发。 科技日报讯 （记者雍黎）记者日前获悉，2025年重庆市智慧医疗装备与前沿技术专项项目启动会 近日在重庆大学举行，首批十大重大装备研制和十大前沿技术研发专项项目（以下简称"'双十'项目"） 在会上签约。项目计划在未来3年到5年通过自主创新突破，带来新产品，推动重庆市智慧医疗装备产业 高质量发展。 其中，重大装备研制项目突出产业化，每个项目支持500万元到1000万元，重点支持研发高端化、 智能化等重大产品与装备；前沿技术研发项目突出产品化，每个项目支持100万元，重点支持预期3年至 5年可转化、产品化的新兴技术项目。 此次启动的首批"双十"项目，主要聚焦高端医疗装备、高效体外诊断、高值医用耗材、人工智能医 疗器械四大领域，进一步凸显企业创新主体。 "我们将针对现有5T及以下磁共振成像系统分 ...

Group 1 - The core viewpoint of the article highlights that Shangya Investment has conducted research on Medtronic Technology, which has been deeply engaged in medical information technology for twenty years and has developed integrated solutions covering over 2,400 medical institutions nationwide [1] - Medtronic Technology is in a phase of scale expansion and structural upgrading, indicating long-term growth potential. Traditional business growth points include smart surgery and emergency rescue, with competitive enhancement measures such as the introduction of large model technology and improved system collaboration capabilities [1] - The company is actively expanding into AI smart healthcare, low-altitude emergency rescue, and health care robotics, ensuring sufficient funding by changing the use of raised funds [1] Group 2 - The smart health care platform developed by Medtronic Technology addresses various needs of the elderly, including emotional support, medical care, health care, and safety monitoring, positioning the company as a comprehensive solution provider for smart health care [1] - The business model of Medtronic Technology is based on the delivery of integrated solutions combining software and hardware, leveraging high-quality medical data resources and complex scenario solution design capabilities in the humanoid robot sector [1] - The low-altitude emergency rescue business has launched an intelligent ED drone rescue solution, with plans for pilot deployment in Suzhou [1]

深圳迈瑞生物医疗电子股份有限公司 投资者关系活动记录表 国家倡导的创新，旨在推动各行业掌握核心技术，为国家发展贡献力量。 迈瑞将继续秉持这一理念，努力提升自身实力，为国家的医疗事业和科技进 步做出更大贡献，同时争取早日实现医疗器械全球排名前十的市场地位。 问：公司究竟有什么独特的"绝招"和卓越的经营能力，能够在激烈的市 场竞争中取得出色的成绩，并保持这种差异化优势？这种优势是否能够长期 维持？ 证券代码：300760 证券简称：迈瑞医疗 编号：2025-004 深圳迈瑞生物医疗电子股份有限公司 投资者关系活动记录表 | | □分析师会议 特定对象调研 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系 | □新闻发布会 路演活动 | | 活动类别 | 现场参观 | | | 投资者开放日、券商策略会等 其他 | | 参与单位名 382 称及人员姓 | 家机构 名参与人员，详见附件清单。 713 | | 名 | | | 2025 时间 | 年 月 日、5 月 日、6 月 日、6 月 日、6 月 5 19-23 26-30 3-5 12-13 18-20 | | 日、6 | ...